Cogent Biosciences, Inc. — Q3 2021 Form 10-Q
Reporting period: Quarter ended September 30, 2021; financial comparisons are with the corresponding 2020 periods. Cogent is a clinical-stage biotechnology company developing precision therapies. Its lead candidate is bezuclastinib (CGT9486); it had no approved products and no product-sale revenue.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Collaboration revenue | $0 | $0.3 million | $0 | $7.9 million |
| Research and development expense | $14.8 million | $5.0 million | $35.4 million | $19.6 million |
| General and administrative expense | $5.0 million | $5.6 million | $14.5 million | $12.1 million |
| Net loss | $19.1 million | $50.0 million | $47.4 million | $63.5 million |
| Net loss per share | $0.48 | $5.07 | $1.25 | $7.56 |
Amounts are shown as losses where applicable. Margins are not meaningful given the absence of product revenue. Lower comparative-period losses mainly reflect the absence in 2021 of the $46.9 million acquired in-process R&D charge recorded in 2020; 2020 also included a $7.5 million asset-disposal gain. Current-period R&D spending increased as bezuclastinib development and manufacturing advanced and headcount grew.
- Cash and liquidity: Cash and cash equivalents were $202.9 million at September 30, 2021, down from $242.2 million at December 31, 2020. Cash, cash equivalents and restricted cash totaled $204.1 million. Current assets were $207.5 million and current liabilities $16.7 million.
- Cash flow, nine months: Operating activities used $38.0 million; investing activities used $1.3 million, primarily for property and lab equipment; financing activities used $0.03 million. Net cash including restricted cash decreased $39.3 million.
- Debt and obligations: No borrowings or debt balance are reported. Total liabilities were $18.1 million, including $3.7 million of operating lease liabilities and a $3.1 million contingent value right (CVR) liability. The filing also describes a Boulder lease, whose accounting commencement was expected in 2022, and a potential tenant-improvement loan of up to approximately $2.3 million.
Material changes and unusual items
- Revenue from legacy collaboration arrangements ended after all performance obligations were completed in 2020; no collaboration revenue was recognized in the first nine months of 2021.
- Year-to-date operating cash use rose from $26.5 million to $38.0 million. The 2020 comparison included substantial noncash acquisition expense and proceeds from asset sales, as well as $110.1 million of financing inflows; 2021 had no comparable capital raise in the reported period.
- Common shares outstanding increased from 32.35 million at year-end 2020 to 39.85 million at September 30, 2021, including conversions of Series A preferred stock. At quarter-end, 103,289 preferred shares remained outstanding, convertible at the holder’s option into common shares subject to limitations.
- The company recorded $1.8 million of other income for the first nine months of 2021, primarily from subleasing office space. The CVR is a Level 3 fair-value liability; remaining settlement is expected to be in cash.
Outlook, management commentary and risks
- Management said $202.9 million of cash and cash equivalents was expected to fund operating expenses and capital expenditures into 2024, based on current plans and assumptions. Separately, the financial-statement note says cash was expected to be sufficient for at least the next 12 months from issuance. The filing does not reconcile these differing horizons.
- Management expects significant future operating losses and rising expenses as clinical and preclinical programs expand. Additional funding may be needed; equity financing could dilute shareholders, while debt or collaboration arrangements could impose restrictions or require rights to be surrendered.
- Clinical plans described include PEAK, a randomized bezuclastinib-plus-sunitinib trial in imatinib-resistant GIST, expected to begin in the second half of 2021; APEX in advanced systemic mastocytosis, initiated in Q2 2021, with preliminary data expected in the first half of 2022; and SUMMIT in non-advanced systemic mastocytosis, initiated in Q4 2021. The filing also reports October 2021 preclinical data and a November 2021 formulation partnership update.
- Key risks include clinical safety, efficacy and timing; regulatory review and approval; manufacturing and supply; competition and intellectual-property protection; ability to raise capital; and possible COVID-19 disruption. The company reported no material COVID-19 impact as of September 30, 2021, while noting future effects remained uncertain. No material legal proceedings were reported.
Important facts for investors to verify
- Whether actual cash burn and updated forecasts support the stated runway into 2024, and how that statement relates to the note’s 12-month liquidity language.
- Clinical trial enrollment, safety, efficacy and timing for PEAK, APEX and SUMMIT, including whether stated milestones were achieved after the filing date.
- Future R&D spending, financing needs and potential dilution, including the remaining preferred-stock conversion capacity and the company’s unused $75 million at-the-market sales agreement as of quarter-end.
- Terms and accounting commencement of the Boulder lease, any tenant-improvement borrowing, and the remaining CVR settlement.